Recalled Artificial Tears Eye Drops Linked to Fourth Death, CDC Reports

Recalled EzriCare Eye Drops Lawsuit Lawyer

Amid continuing concerns about bacterial contamination that resulted in an Artificial Tears eye drops recall earlier this year, federal disease experts have confirmed additional reports involving severe infections among users nationwide, and indicate that at least four people have died.

The U.S. Centers for Disease Control and Prevention (CDC) issued an update on the Artificial Tears infection outbreak on May 15, indicating that the agency is aware of at least 81 infections linked to the recalled eye drops in 18 different states. In addition to four deaths linked to severe infections that resulted from the eye drops, the agency indicates that a number of other cases involved hospitalization or individuals who suffered vision loss, with at least another four cases resulting in the need for surgical eye removal.

The Artificial Tears recall was first issued in February 2023, leading health officials to warn consumers and medical providers to immediately stop using EzricCare and Delsam Pharma Artificial Tears eye drops, which have been found to be contaminated with carbapenem-resistant Pseudomonas aeruginosa.

Artificial Tears Infection Recall

Information about the Artificial Tears infection outbreak first surfaced in late January 2023, when the CDC identified a cluster of individuals experiencing bacterial infections after using EzriCare eye drops. This immediately led to calls for a recall, and a steadily growing number of Artificial Tears lawsuits brought both by individuals diagnosed with infections, as well as consumer class action claims that seek economic damages and medical monitoring.

"*" indicates required fields

"*" indicates required fields

The recall initially impacted 15 ml bottles of EzriCare Artificial Tears, sold in a blue box, and Delsam Phama Artificial Tears, sold in a white box. However, several weeks later, the FDA expanded the recall to include Delsam Pharma Artificial Eye Ointment as well.

The EzriCare and Delsam Pharma Artificial Tears were sold through Amazon.com, Walmart and other nationwide retails, and have been widely used by consumers for symptoms of dry or itchy eye symptoms, or other eye conditions, such as glaucoma or ocular hypertension. The recalled eye drops were also distributed directly to hospitals, healthcare centers and nursing homes nationwide.

CDC investigators began looking at the Artificial Tears products after several Pseudomonas aeruginosa outbreaks in nursing homes surfaced in Connecticut and Utah, and have indicated that elderly or infirmed individuals may face the greatest risk. That trend continued in the lastest update, the CDC reports.

Health officials indicate that all consumers should be aware of the potential eye infection symptoms, which may include;

  • Yellow, green, or clear discharge from the eye
  • Eye pain or discomfort
  • Redness of the eye or eyelid
  • Feeling of something in your eye (foreign body sensation)
  • Increased sensitivity to light
  • Blurry vision

Artificial Tears Eye Drops Lawsuits

As the number of reported eye drops infections continue to rise, a series of eye drops lawsuits have been filed in recent weeks, claiming the manufacturers failed to perform proper microbial testing, allowing the products to be sold directly to consumers containing Pseudomonas aeruginosa.

The Artificial Tears lawsuits indicate that, as a result, consumers have now suffered eye infections that have resulted in permanent vision loss and other injuries.

Lawyers are actively investigating potential eye drop infection lawsuits against the manufacturers and distributors of EzriCare and Delsam Pharma’s eye drops for multiple injuries and side effects caused by the contamination, including;

  • Eye Infection
  • Partial Blindness
  • Permanent Blindness
  • Bloodstream Infection
  • Other injuries caused by the eye drops
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Nitrous oxide injury lawsuits are emerging as medical evidence links recreational use of the gas to nerve damage that can cause numbness, balance problems and difficulty walking, often without adequate side effect warnings.
A federal judge has scheduled a series of Bard PowerPort trials between April 2026 and February 2027, which will focus on allegations that defective design flaws made the devices susceptible to infections, fractures and migration.
A federal judge is calling for dozens of attorneys to reapply for leadership positions in Depo-Provera brain tumor litigation before their appointments expire in March.